Article Details

First patient dosed in Clarity's registrational Phase III prostate cancer trial with Cu-64 SAR-bisPSMA

Retrieved on: 2023-12-22 20:00:47

Tags for this article:

Click the tags to see associated articles and topics

First patient dosed in Clarity's registrational Phase III prostate cancer trial with Cu-64 SAR-bisPSMA. View article details on hiswai:

Excerpt

Executive Chairman Investor/Media Relations ataylor@claritypharm.com ... For Public Relations · For IR & Compliance · For Agency · For Small Business ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo